1. Karki M., Sun J., Yadav C.P., Zhao B. Large and giant pituitary adenoma resection by microscopic trans-sphenoidal surgery: surgical outcomes and complications in 123 consecutive patients. J Clin Neurosci. 2017; 44: 310–4. DOI: https://doi.org/10.1016/j.jocn.2017.07.015
2. Freda P.U., Bruce J.N., Reyes-Vidal C., Singh S., et al. Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly. Pituitary. 2021; 24 (2): 170–83. DOI: https://doi.org/10.1007/s11102-020-01094-4
3. Lu L., Wan X., Xu Y., Chen J., et al. Prognostic factors for recurrence in pituitary adenomas: recent progress and future directions. Diagnostics (Basel). 2022; 12 (4): 977. DOI: https://doi.org/10.3390/diagnostics12040977
4. Watts A.K., Easwaran A., McNeill P., Wang Y.Y., et al. Younger age is a risk factor for regrowth and recurrence of nonfunctioning pituitary macroadenomas: results from a single Australian centre. Clin Endocrinol. 2017; 87: 264–71. DOI: https://doi.org/10.1111/cen.13365
5. Park S.H., Ku C.R., Moon J.H., Kim E.H., et al. Age- and sex-specific differences as predictors of surgical remission among patients with acromegaly. J Clin Endocrinol Metab. 2018; 103 (3): 909–16. DOI: https://doi.org/10.1210/jc.2017-01844
6. Boguslawska A., Gilis-Januszewska A., Godlewska M., Nowak A., et al. Sex and age differences among patients with acromegaly. Pol Arch Intern Med. 2022; 132 (6): 16232. DOI: https://doi.org/10.20452/pamw.16232
7. Zhang C., Heng X., Neng W., Chen H., et al. Prediction of high infiltration levels in pituitary adenoma using MRI-based radiomics and machine learning. Chin Neurosurg J. 2022; 8: 21. DOI: https://doi.org/10.1186/s41016-022-00290-4
8. Raverot G., Dantony E., Beauvy J., Vasiljevic A., et al. Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab. 2017; 102 (9): 3368–74. DOI: https://doi.org/10.1210/jc.2017-00773
9. Wang M., Shen M., He W., Yang Y., et al. The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly. Endocr J. 2016; 63 (9): 819–34. DOI: https://doi.org/10.1507/endocrj.EJ16-0175
10. Chen Y., Cai f., Cao J., Gao F., et al. Progression after transnasal sphenoidal surgical treatment of large and giant pituitary adenomas and establish a nomogram to predict tumor prognosis. Front Endocrinol (Lausanne). 2021; 12: 793337. DOI: https://doi.org/10.3389/fendo.2021.793337
11. Campana C., van Koetsveld P.M., Feelders R.A., de Herder W.W., et al. Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study. Eur J Endocrinol. 2022; 187 (3): 399–411. DOI: https://doi.org/10.1530/EJE-22-0339
12. Colao A., Auriemma R.S., Pivonello R. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary. 2016; 19: 210–21. DOI: https://doi.org/10.1007/s11102-015-0677-y
13. Petersenn S., Houchard A., Sert C., Caron P.J., et al. Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary. 2020; 23 (2): 171–81. DOI: https://doi.org/10.1007/s11102-019-01020-3
14. Rass L., Rahvar A-H., Matschke J., Satger W., et al. Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy? Hormones (Athens). 2022; 21 (1): 79–89. DOI: https://doi.org/10.1007/s42000-021-00327-w
15. Colao A., Auriemma R.S., Lombardi G., Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011; 32: 247–71. DOI: https://doi.org/10.1210/er.2010-0002
16. Puig-Domingo M., Bernabéu I., Picó A., Biagetti B., et al. Pasireotide in the personalized treatment of acromegaly.https://pubmed.ncbi.nlm.nih.gov/33796079/ Front Endocrinol (Lausanne). 2021; 12: 648411. DOI: https://doi.org/10.3389/fendo.2021.648411
17. Chiloiro S., Costa D., Lauretta R., Mercuri V., et al. Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly. Endocrine. 2022; 78 (2): 343–53. DOI: https://doi.org/10.1007/s12020-022-03158-w
18. Coopmans E.C., Schneiders J.J., El-Sayed N., Erler N.S., et al. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur J Endocrinol. 2020; 182 (6): 595–605. DOI: https://doi.org/10.1530/EJE-19-0840
19. Kasuki L., Wildemberg L.E., Gadelha M. Management of endocrine disease: personalized medicine in the treatment of acromegaly. Eur J Endocrinol. 2018; 178 (3): R89–100. DOI: https://doi.org/10.1530/EJE-17-1006
20. Pronin E.V., Antsiferov M.B., Alekseeva T.M., Urusova L.S., et al. Optimization of drug treatment of acromegaly (clinical and morphological comparison). Farmateka [Pharmateca]. 2022; 29 (4): 44–52. DOI: https://doi.org/10.18565/pharmateca.2022.4.44-52 (in Russian)
21. Liu W., Xie L., He M., Shen M., et al. Expression of somatostatin receptor 2 in somatotropinoma correlated with the short-term efficacy of somatostatin analogues. Int J Endocrinol. 2017; 2017: 9606985. DOI: https://doi.org/10.1155/2017/9606985
22. Tortora F., Negro A., Grasso L.F.S., Colao A., et al. Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas. Gland Surg. 2019; 8 (suppl 3): S150–8. DOI: https://doi.org/10.21037/gs.2019.06.04
23. Störmann S., Schopohl J., Bullmann C., Terkamp C., et al. Multicenter, observational study of lanreotide autogel for the treatment of patients with acromegaly in routine clinical practice in Germany, Austria and Switzerland. Exp Clin Endocrinol Diabetes. 2021; 129 (3): 224–33. DOI: https://doi.org/10.1055/a-1247-4713
24. Durmus E.T., Atmaca A., Kefeli M., Caliskan S., et al. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: a clinicopathological study. Growth Horm IGF Res. 2022; 67: 101502. DOI: https://doi.org/10.1016/j.ghir.2022.101502
25. Amarawardena W.K.M.G., Liyanarachchi K.D., Newell-Price J.D.C., Ross R.J.M., et al. Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly. Endocrinol Diabetes Metab Case Rep. 2017; 2017 (1): 17-0067. DOI: https://doi.org/10.1530/EDM-17-0067
26. Venegas-Moreno E., Vazquez-Borrego M.C., Dios E., Gros-Herguido N., et al. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. J Cell Mol Med. 2018; 22 (3): 1640–9. DOI: https://doi.org/10.1111/jcmm.13440
27. Kontogeorgos G., Markussis V., Thodou E., Kyrodimou E., et al. Association of pathology markers with somatostatin analogue responsiveness in acromegaly. Int J Endocrinol.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529452/ 2022; 2022: 8660470. DOI: https://doi.org/10.1155/2022/8660470
28. Kasuki L., Wildemberg L.E., Neto L.V., Marcondes J., et al. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur J Endocrinol. 2013; 169 (2): 217–23. DOI: https://doi.org/10.1530/EJE-13-0349
29. Gil J., Marques-Pamies M., Sampedro M., Webb S.M., et al. Data mining analyses for precision medicine in acromegaly: a proof of concept. Sci Rep. 2022; 12 (1): 8979. DOI: https://doi.org/10.1038/s41598-022-12955-2
30. Ezzat S., Caspar-bell G.M., Chik C.L. Denis M.-C., et al. Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline. Endocr Pract. 2019; 25 (4): 379–93. DOI: https://doi.org/10.4158/ep-2018-0500